Amarin Corp PLC\UK is listed today as Amarin Corporation: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2009 | $70 M | No. 1 | $50 to $250 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Amarin Corporation, its revenue in fiscal 2025 came from these product and service lines: Licensing and Royalty Revenue $30.89 million (14%).
Annual report (SEC XBRL) · Dec 2025
Amarin Corp PLC\UK had no revenue when it filed its newest notice of a funding round (Oct 2009).
SEC Form D (revenue range) · Oct 2009
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Oct 2009
Products and services#
No products or services of Amarin Corp PLC\UK are on record.
Investors#
No investor of Amarin Corp PLC\UK is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 36 investors.
Largest shareholders today
Institutions holding Amarin Corporation shares, as of Sep 30, 2026.
- Sarissa Capital Management LP$17 M6.24%
- Acadian Asset Management LLC$10 M3.56%
- Kynam Capital Management, LP$7 M2.59%
- Brooklands Fund Management Ltd$3 M1.06%
- Waterfront Wealth Inc.$3 M1.04%
- Susquehanna International Group, LLP$3 M0.97%
- Morgan Stanley$2 M0.92%
- Millennium Management LLC$2 M0.86%
- Eversept Partners, LP$2 M0.70%
- BNP Paribas Financial Markets$1 M0.34%
- LCM Capital Management Inc$1 M0.29%
- Citadel Advisors LLC$1 M0.28%
- R Squared Ltd$1 M0.24%
- George Kaiser Family Foundation$1 M0.22%
- Renaissance Technologies LLC$1 M0.22%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Alan L. Cooke | CFO | Oct 2009 |
| Thomas G. Lynch | Chief Executive Officer and Chairman | Oct 2009 |
| Carl L. Gordon | Director | Oct 2009 |
| James I. Healy | Director | Oct 2009 |
| Joseph L. Anderson | Director | Oct 2009 |
| Lars L. Ekman | Director | Oct 2009 |
| Manus L. Rogan | Director | Oct 2009 |
| Thomas G. Lynch | Chief Executive Officer and Chairman | Oct 2009 |
About
Biopharmaceutical company.
Went public since 2011. Its SEC number is that of a company listed on a stock exchange.